Resting energy expenditure in the risk assessment of anticancer treatments

By a News Reporter-Staff News Editor at Pharma Investments, Ventures & Law Weekly -- New research on Drugs and Therapies - Cancer Therapy is the subject of a report. According to news reporting originating from Paris, France, by NewsRx correspondents, research stated, “Alterations of nutritional and performance status (PS) are associated with higher risk of chemotherapy toxicity. Increased resting energy expenditure (REE) is frequent in cancer patients and may contribute to cachexia.”

Our news editors obtained a quote from the research from Paris-Descartes University, “We investigated whether abnormal energetic metabolism could predict early acute limiting toxicities (ELT) of anticancer treatments. In this observational monocentric study, REE was measured by indirect calorimetry before treatment initiation. Based on the ratio of measured REE to REE predicted by the Harris-Benedict formula, patients were classified as hypometabolic (<90%), normometabolic (90-110%) or hypermetabolic (>110%). Body mass index, weight loss, PS, albumin, transthyretin, C-reactive protein (CRP) and muscle mass (CT-scan) were studied. Were defined as ELT any unplanned hospitalization or any adverse event leading to dose reduction or discontinuation during the first cycle of treatment. We enrolled 277 patients: 76% had metastatic disease; 89% received chemotherapy and 11% targeted therapy; 29% were normometabolic, 51% hypermetabolic and 20% hypometabolic. Fifty-nine. patients (21%) experienced an ELT. Toxicity was associated with abnormal metabolism (vs normal: OR = 2.37 [1.13-4.94], p = 0.023), PS (2-3 vs 0-1: OR = 2.04 [1.12-3.74], p = 0.023), albumin (<35 vs >= 35 g/I: OR = 2.39 [1.03-5.54], p = 0.048), and inflammation (CRP >= 10 vs <10 mg/I: OR = 2.43 [1.35, 4.38], p = 0.004). To predict toxicity, the most sensitive parameter was the REE (83%) followed by PINI (63%), GPS (59%), CRP (55%), PS (41%), NRI (37%), and albumin (16%). In multivariate analysis, elevated CRP was an independent predictor of toxicity (p = 0.047).”

According to the news editors, the research concluded: “Abnormal basal energy metabolism identifies patients at higher risk of treatment-related acute complications.”

For more information on this research see: Resting energy expenditure in the risk assessment of anticancer treatments. Clinical Nutrition , 2018;37(2):558-565. Clinical Nutrition can be contacted at: Churchill Livingstone, Journal Production Dept, Robert Stevenson House, 1-3 Baxters Place, Leith Walk, Edinburgh EH1 3AF, Midlothian, Scotland. (Elsevier - www.elsevier.com; Clinical Nutrition - http://www.journals.elsevier.com/clinical-nutrition/)

The news editors report that additional information may be obtained by contacting A. Jouinot, Paris Descartes Univ, USPC, Paris Center Teaching Hosp, Canc Res Personalized Med CARPEMMed Oncol Department, Paris, France. Additional authors for this research include C. Vazeille, J.P. Durand, O. Huillard, P. Boudou-Rouquette, R. Coriat, J. Chapron, N. Neveux, J.P. De Bandt, J. Alexandre, L. Cynober and F. Goldwasser.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.clnu.2017.01.007. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

CITATION: (2018-04-29), New Cancer Therapy Study Results from Paris-Descartes University Described (Resting energy expenditure in the risk assessment of anticancer treatments), Pharma Investments, Ventures & Law Weekly, 26, ISSN: 0000-0000, BUTTER® ID: 015529394

From the newsletter Pharma Investments, Ventures & Law Weekly.
https://www.newsrx.com/Butter/#!Search:a=15529394

This is a NewsRx^® article created by NewsRx^® and posted by NewsRx^®. As proof that we are NewsRx^® posting NewsRx^® content, we have added a link to this steemit page on our main corporate website. The link is at the bottom left under "site links" at https://www.newsrx.com/NewsRxCorp/.

We have been in business for more than 20 years and our full contact information is available on our main corporate website.

We only upvote our posts after at least one other user has upvoted the article to increase the curation awards of upvoters.

NewsRx^® offers 195 weekly newsletters providing comprehensive information on all professional topics, ranging from health, pharma and life science to business, tech, energy, law, and finance. Our newsletters report only the most relevant and authoritative information from qualified sources.

View Newsletter Titles

About NewsRx^® and Contact Information